News
CLPBY
6.80
+0.59%
0.04
Weekly Report: what happened at CLPBY last week (0406-0410)?
Weekly Report · 2d ago
Weekly Report: what happened at CLPBY last week (0330-0403)?
Weekly Report · 04/06 09:28
Weekly Report: what happened at CLPBY last week (0323-0327)?
Weekly Report · 03/30 09:28
*Coloplast Raised to Buy From Neutral by UBS
Dow Jones · 03/24 09:29
Weekly Report: what happened at CLPBY last week (0316-0320)?
Weekly Report · 03/23 09:27
Coloplast: The Market Is Throwing Away A High-Quality Compounder
Seeking Alpha · 03/17 11:41
Weekly Report: what happened at CLPBY last week (0309-0313)?
Weekly Report · 03/16 09:26
Weekly Report: what happened at CLPBY last week (0302-0306)?
Weekly Report · 03/09 09:27
Weekly Report: what happened at CLPBY last week (0223-0227)?
Weekly Report · 03/02 09:27
Weekly Report: what happened at CLPBY last week (0216-0220)?
Weekly Report · 02/23 09:26
Weekly Report: what happened at CLPBY last week (0209-0213)?
Weekly Report · 02/16 09:26
Coloplast A/S reports Q1 results
Seeking Alpha · 02/10 17:22
Weekly Report: what happened at CLPBY last week (0202-0206)?
Weekly Report · 02/09 09:27
Coloplast Narrows FY2026 Sales Guidance from $4.541B-$4.585B to $4.541B; Sees ~4% YoY Revenue Growth
Benzinga · 02/06 10:09
Coloplast Q1 Adj. EPS $0.09, Inline, Sales $1.098B Up From $1.005B YoY
Benzinga · 02/06 09:59
Coloplast Reported Revenue for 2026 FY is expected to up by 4 % YoY
Benzinga · 02/06 09:51
Earnings Preview: Coloplast
Benzinga · 02/05 14:01
Weekly Report: what happened at CLPBY last week (0126-0130)?
Weekly Report · 02/02 09:27
Weekly Report: what happened at CLPBY last week (0119-0123)?
Weekly Report · 01/26 09:27
Nordic Equities Tumble on Trump Greenland Tariffs -- Market Talk
Dow Jones · 01/19 11:33
More
Webull provides a variety of real-time CLPBY stock news. You can receive the latest news about Coloplast As Drc through multiple platforms. This information may help you make smarter investment decisions.
About CLPBY
Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.